Geffy is a prescription medication used to treat advanced non-small cell lung cancer (NSCLC) in patients with epidermal growth factor receptor (EGFR) mutations.
Composition:
Geffy is an oral tablet containing 250mg of gefitinib per tablet.
Mechanism of Action:
Gefitinib works by:
- Inhibiting the activity of the EGFR protein, which is a key driver of cancer cell growth and survival
- Blocking the EGFR signaling pathway, which helps to prevent cancer cell growth and proliferation
Uses:
Geffy is used to treat:
- Advanced non-small cell lung cancer (NSCLC) in patients with EGFR mutations
- Locally advanced or metastatic NSCLC in patients with EGFR mutations who have not received previous chemotherapy
Dosage:
The recommended dosage of Geffy is:
- 250mg taken orally once daily, with or without food
- Continue treatment until disease progression or unacceptable toxicity
Side Effects:
Common side effects of Geffy include:
- Diarrhea
- Skin rash
- Nail problems
- Fatigue
- Headache
- Dry mouth
- Increased risk of infection
- Increased risk of bleeding
- Low white blood cell count
- Low platelet count
- Liver problems
- Kidney problems
Recommendation:
Geffy is recommended for patients with advanced NSCLC and EGFR mutations who have not responded to other treatments. Patients should also be advised to monitor their blood counts and liver function regularly during treatment.
Important Note:
Patients should not take Geffy if they have a history of severe allergic reactions, liver problems, or kidney problems. Patients should also inform their healthcare provider if they have any underlying medical conditions, such as heart problems or lung problems, before taking Geffy.
Some common brands of gefitinib include:
- Iressa (AstraZeneca)
- Gefitinib (various manufacturers)
Please note that Geffy is not available in all markets and may be approved for different indications and dosages in different regions.
Reviews
There are no reviews yet.